Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Short-term Investments (2017 - 2025)

Historic Short-term Investments for Lineage Cell Therapeutics (LCTX) over the last 9 years, with Q3 2025 value amounting to $23000.0.

  • Lineage Cell Therapeutics' Short-term Investments fell 9953.64% to $23000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $23000.0, marking a year-over-year decrease of 9953.64%. This contributed to the annual value of $2.0 million for FY2024, which is 393200.0% up from last year.
  • According to the latest figures from Q3 2025, Lineage Cell Therapeutics' Short-term Investments is $23000.0, which was down 9953.64% from $17000.0 recorded in Q2 2025.
  • Over the past 5 years, Lineage Cell Therapeutics' Short-term Investments peaked at $46.5 million during Q4 2022, and registered a low of $17000.0 during Q2 2025.
  • Over the past 5 years, Lineage Cell Therapeutics' median Short-term Investments value was $4.3 million (recorded in 2021), while the average stood at $9.5 million.
  • Per our database at Business Quant, Lineage Cell Therapeutics' Short-term Investments crashed by 9989.25% in 2023 and then skyrocketed by 393200.0% in 2024.
  • Over the past 5 years, Lineage Cell Therapeutics' Short-term Investments (Quarter) stood at $2.6 million in 2021, then skyrocketed by 1678.29% to $46.5 million in 2022, then tumbled by 99.89% to $50000.0 in 2023, then soared by 3932.0% to $2.0 million in 2024, then crashed by 98.86% to $23000.0 in 2025.
  • Its Short-term Investments was $23000.0 in Q3 2025, compared to $17000.0 in Q2 2025 and $19000.0 in Q1 2025.